Rani Therapeutics to Participate in the Chardan Healthcare Conference
Rani Therapeutics (Nasdaq: RANI) will participate in a fireside chat at the Chardan Healthcare Conference on October 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rani Therapeutics (Nasdaq: RANI) will participate in a fireside chat at the Chardan Healthcare Conference on October 20, 2026. The session is scheduled for 1:00 p.m. E.T. in New York. CEO Talat Imran, CFO Nicholas Maestas and Chief Business Officer Kate McKinley will present; the format also includes one-on-one meetings. A live webcast will be available through the company's Investor Relations website, with a replay afterward.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in a fireside chat at the upcoming Chardan Healthcare Conference. Details below:
Chardan Healthcare Conference
Date: Tuesday, October 20, 2026 at 1:00pm E.T.
Location: New York, New York
Presenter: Chief Executive Officer, Talat Imran, Chief Financial Officer, Nicholas Maestas, and Chief Business Officer, Kate McKinley
Format: Fireside Chat and 1x1 Meetings
Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the presentation.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
